The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by rearranging from a mature unliganded state, through receptor-bound intermediates, to a post-fusion state. As the sole viral antigen on the HIV-1 virion surface, Env is both the target of neutralizing antibodies and a focus of vaccine efforts. Here we report the structure at 3.5 Å resolution for an HIV-1 Env trimer captured in a mature closed state by antibodies PGT122 and 35O22. This structure reveals the prefusion conformation of gp41, indicates rearrangements needed for fusion activation, and defines parameters of immune evasion and immune recognition. Pre-fusion gp41 encircles amino-and carboxy-terminal strands of gp120 with four helices that form a membrane-proximal collar, fastened by insertion of a fusion peptide-proximal methionine into a gp41-tryptophan clasp. Spike rearrangements required for entry involve opening the clasp and expelling the termini. N-linked glycosylation and sequence-variable regions cover the pre-fusion closed spike; we used chronic cohorts to map the prevalence and location of effective HIV-1-neutralizing responses, which were distinguished by their recognition of N-linked glycan and tolerance for epitope-sequence variation.
Over the last 50 years, more than 70 million people have been infected or killed by the human immunodeficiency virus type 1 (HIV-1) 1 . A dominant contributing factor has been the molecular trickery of the HIV-1 envelope (Env) spike, a type I fusion machine that facilitates virus entry into cells by interacting with host cellular receptors and fusing membranes of virus and host cell (reviewed in ref. 2) . Despite its exposed position on the viral membrane and the generation of narrow-breadth neutralizing antibody responses throughout the course of HIV-1 infection, the evolving HIV-1 Env spike successfully evades most antibodymediated neutralization 3 . This evasion is, to a large degree, responsible for the difficulty in developing an effective HIV-1 vaccine.
Initially synthesized as a gp160 precursor, which is cleaved into gp120 and gp41 subunits, the trimeric HIV-1 Env spike displays unusual posttranslational processing, including the addition of 25-30 N-linked glycans per gp120-gp41 protomer 4 , tyrosine sulphation 5 , and slow signal peptide cleavage 6 . Env rearranges from a pre-fusion mature closed state that evades antibody recognition through intermediate open states that bind to receptors, CD4 and co-receptor (either CCR5 or CXCR4), to a post-fusion state (reviewed in ref. 2) . Over the last 20 years, substantial atomic-level detail has been obtained on these states, including structures of receptor-bound gp120 7 , post-fusion gp41 8, 9 , and most recently the trimeric arrangement of pre-fusion gp120 along with two gp41 helices, one of which was aligned in sequence 10, 11 . The pre-fusion structure of gp41 has, however, resisted atomic-level analysis. Because the primary structural rearrangement driving membrane fusion is the gp41 transition from pre-fusion to post-fusion conformations, the lack of a pre-fusion gp41 structure has stymied attempts to provide a coherent picture of the conformational rearrangements the spike undergoes to facilitate entry.
Here we use neutralizing antibodies PGT122 12 and 35O22 13 to capture the HIV-1 spike in a pre-fusion mature closed state. We obtained crystals of the antigen-binding fragments (Fabs) of these two antibodies in complex with a soluble, cleaved Env trimer construct (BG505 SOSIP. 664) [14] [15] [16] and determined its atomic-level structure. Examination of this structure in the context of previously determined gp120 and gp41 structures affords a mechanistic understanding of the conformational transitions the spike undergoes to facilitate virus entry. We delineated aggregate parameters of glycan shielding and genetic variation and used infected donor serum to determine where the immune system succeeds in recognizing the HIV-1 spike. Analysis of the pre-fusion HIV-1 Env structure and its conformational rearrangements, combined with an understanding of its evasion from and vulnerabilities to the immune system, reveal similarities to other type I viral fusion machines as well as features of recognition by the human immune system unique to this important vaccine target.
Structure determination and overall structure
Atomic-level information for virtually all of the HIV-1 Env ectodomain in its pre-fusion conformation has been obtained from antibody-bound complexes (Extended Data Fig. 1a ). The recently determined crystal structure 10 of a soluble cleaved HIV-1 Env based on the BG505 SOSIP. 664 construct was no exception; in particular, while an artificial disulphide and other modifications of the SOSIP.664 construct were critical to production of a homogeneous, soluble, cleaved trimer 17 , antibody PGT122 appeared to facilitate crystallization 10 . Diffraction from crystals of the PGT122 complex, however, extended to only 4.7 Å resolution, hampering the trace of non-helical regions of gp41 as well as the placement and registry of side chains 10 . To obtain improved crystals, we explored the addition of antibody 35O22, which recognizes a gp120-gp41 epitope 13 . Addition of 35O22 to PGT122-bound viral spike in the membrane-bound virion context showed single-molecule fluorescence resonance energy transfer (smFRET) responses that closely resembled those of the mature native unliganded spike (Extended Data Fig. 1b) 18 . In the context of crystallization, addition of 35O22 to the PGT122-BG505 SOSIP.664 complex led to ternary complex crystals in space group P6 3 . Although diffraction was anisotropic, we succeeded in collecting ,3.5 Å data from a single crystal (Extended Data Table 1 ). Structure solution by molecular replacement with free structures of Fab PGT122 19 , Fab 35O22 13 and gp120 20 revealed a double antibody-bound gp120-gp41 protomer to occupy the asymmetric unit and led to an R work / R free of 21.35%/24.80%.
Overall, the HIV-1 spike forms a three-blade propeller, capped at its membrane-distal apex by antibody PGT122 and at the membraneproximal end by antibody 35O22 (Fig. 1 and Extended Data Fig. 2a, b ). Protomer interactions occur through assembled variable regions, V1, V2 and V3, which comprise the trimer association domain 21 at the membrane-distal portion of the spike, and also through gp41, primarily between helical interactions around the trimer axis 10, 11 . No trimeric interactions are contributed by the gp120 core; indeed, a cleft or opening is found under the trimer association domains along the threefold axis where such associations might occur. Trimeric pre-fusion gp41 forms a platform through which the gp120 termini extend towards the viral membrane. Unusually slow signal peptide cleavage 6 , which keeps the N terminus of gp120 proximal to the membrane, may facilitate folding of pre-fusion HIV-1 Env.
Pre-fusion structure of gp41
Pre-fusion gp41 wraps its hydrophobic core around extended N and C termini-strands of gp120 ( Fig. 2a ). It forms a four-helix collar comprising helices a6 (Met 530 gp41 -Asn 543 gp41 ), a7 (Gly 572 gp41 -Ile 595 gp41 ), a8 (Leu 619 gp41 -Trp 623 gp41 ), and a9 (Trp 628 gp41 -Asp 664 gp41 ) (the numbering of pre-fusion gp41 helices and strands continues the nomenclature established for the gp120 subunit, which ends with helix a5 and strand b26; for clarity, the molecule is named after each residue number). The first residue of gp41 visible in electron density corresponds to Val 518 gp41 , in the fusion peptide. An extended stretch connects to Leu 523 gp41 , which interacts hydrophobically with Trp 45 gp120 and Ile 84 gp120 , both of which are part of the seven-stranded b-sandwich around which the gp120 inner domain is organized 22, 23 . The main chain of gp41 follows gp120 strand b0 away from the trimer axis towards the viral membrane until residue Met 530 gp41 , where the fold reverses itself and extends through a6 towards the trimer axis and away from the viral membrane. Density between residues 547 gp41 and 569 gp41 is sparse (Extended Data Fig. 3a, b ), and ultimately connects to helix a7, which forms a parallel coiled-coil about the trimer axis. At the end of a7 is the gp41 cysteine loop (spanned by the Cys 598 gp41 -Cys 604 gp41 disulphide), whose C-terminal residues initiate strand b27 (Leu 602 gp41 -Thr 606 gp41 ), which forms hydrogen bonds in an anti-parallel fashion with strand b 4 (bstrand negative 4) from the N terminus of gp120. and 35O22 antibodies. One protomer and associated Fabs are shown in ribbon and stick representation, a second protomer in surface representation, and the third protomer in grey. Residues comprising the refined HIV-1 Env model are displayed on the bar, with beginning and final ordered residue of each segment labelled; vertical lines demark termini of the mature ectodomain subunits; unmodelled regions, which show residues disordered or not present in the BG505 SOSIP.664 construct, as well as glycans, which are disordered or not present, are shown in grey. 35O22 and PGT122 interactions with the HIV-1 Env trimer are shown in Extended Data Fig. 9a -f, and bound versus unbound Fabs are shown in Extended Data Fig. 9g . igure 2 | Pre-fusion structure of gp41. a, gp41 forms a four-helix collar, which wraps around extended N and C termini of gp120. Both gp120 (red) and gp41 (rainbow from blue to orange) are depicted in ribbon representation, with select residues and secondary structure labelled (additional labels are shown in Extended Data Fig. 10 ). The location of the trimer axis is indicated with a '3' inside a triangle. The orientation shown here is similar to that of Fig. 1 , with perpendicular orientations provided in b and c. Zoom insert: the gp41 collar is clasped by the insertion of Met 530 gp41 into a tryptophan sandwich and by the alignment of helices a6 and a8. 2F o 2 F c electron density for clasp residues is depicted at 1s. b, gp41 holds the N and C termini of gp120 in its hydrophobic core. Colouring and representation are the same as in a, except that hydrophobic side chains are shown in stick representation and the orientation is rotated 90u, to depict the view from the viral membrane. c, gp41trimer interfaces as viewed from side in ribbon and surface representation. Overall, the pre-fusion structure of gp41 and its trimeric arrangement appear to have no close structural relatives in the Protein Data Bank (Supplementary  Table 2 ). N618, N611 and N637 indicate gp41 residues with attached N-linked glycans (see Fig. 1 bar).
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disulphide ('SOS') 14 between residues 501 gp120 and 605 gp41 welds the C terminus of gp120 to the membrane-proximal end of strand b 4 ( Fig. 2a ). Upon passing the gp120 termini, gp41 reaches a8, whose C terminus aligns spatially with the N terminus of a6. After a8, the a9 helix reverses direction, again wrapping past the N and C termini of gp120, before extending horizontally along the edge of the spike to reach the gp120 termini from a neighbouring protomer.
Topologically, the gp41 subunit completes a single circle around the gp120 termini with the insertion of a hydrophobic prong comprising the side chain of Met 530 gp41 (which is located at the N terminus of a6, proximal to the fusion peptide), into a triple-tryptophan clasp formed by Trp 623 gp41 (from the C terminus of a8), Trp 628 gp41 (from the N terminus of a9) and Trp 631 gp41 (one turn into a9) ( Fig. 2a insert) . The alignment of helices a6 and a8 provides electrostatic complementarity that helps to stabilize the neighbouring methionine-tryptophan clasp.
Within a single protomer, the buried surface area between gp41 and gp120 totals 5,270 Å 2 , including 216 Å 2 from glycan-protein interactions (Supplementary Table 1 ). A substantial portion of this is hydrophobic: gp41 essentially wraps its hydrophobic core around the N and C termini of gp120 ( Fig. 2b ). Trimer interfaces also bury a large surface area (3,140 Å 2 contributed by each protomer, comprising 1,920 Å 2 from the gp41-gp41 interface, 861 Å 2 from the gp120-gp120 interface and 360 Å 2 from the gp120-gp41 interface) (Extended Data Fig. 2c-f ). Close to the trimer axis, these involve helix a7, as well as the N-terminal portion of the gp41-cysteine loop. Further from the trimer axis, interactions involve a9. Other than interactions of a7, most inter-protomer interactions are hydrophilic ( Fig. 2c ).
Pre-fusion to post-fusion gp41 transition
To understand the conformational transition from pre-fusion to postfusion gp41, we compared the gp41 pre-fusion structure in our antibody-bound HIV-1 Env trimer with previously determined post-fusion structures 8, 9, 24, 25 (Fig. 3 ). Post-fusion gp41 comprises two helices, HR1 and HR2 (Fig. 3a) ; these form a trimeric six-helical bundle, with HR1 helices arranged as an interior parallel coiled-coil, and exterior HR2 helices packed in an anti-parallel fashion to bring N-terminal fusion peptides and C-terminal transmembrane regions into proximity. Distance difference analysis 26 (Fig. 3b ) of pre-fusion and post-fusion structures indicated two regions of structural similarity, corresponding to the prefusion a7 helix aligned with the C-terminal half of the post-fusion HR1 helix ( Fig. 3c , left) and the pre-fusion a9 helix aligned with much of the post-fusion HR2 helix ( Fig. 3c, right) .
Superposition of pre-fusion a7 and post-fusion HR1 placed residues 569 gp41 -593 gp41 within 5 Å , with a root-mean-square deviation (r.m.s.d.) of 1.35 Å ( Fig. 3c , left). For this superposition to occur, Ca-movements of over 80 Å are required for the gp41 fusion peptide and a6 helix as well as for the C-terminal portion of the a9 helix. Notably, this superposition preserves the coiled-coil trimeric interactions of both pre-fusion and post-fusion molecules and thus is likely to mimic the natural conformational transition that occurs during membrane fusion. Meanwhile, a, BG505 sequence 46 of gp41, with pre-fusion and post-fusion secondary structure. Fusion peptide (FP) is underlined and labelled green. Several postfusion gp41 structures have been determined ranging from a minimal, protease-treated, crystal structure (residues 556 gp41 -581 gp41 ; 628 gp41 -661 gp41 ; PDB ID 1AIK 8 ) with 80% sequence identity to BG505 46 to a more complete gp41 structure (residues 531 gp41 -581 gp41 ; 624 gp41 -681 gp41 ; PDB ID 2X7R 24 ) and an NMR structure that includes the cysteine loop (residues 539 gp41 -665 gp41 ; PDB ID 2EZO 25 ) of the simian immunodeficiency virus (SIV), which shares 48% sequence identity with BG505 46 and is substantially similar to the HIV-1 structures (less than 1 Å Ca r.m.s.d. between overlapping residues of 1AIK and 2EZO). The post-fusion structure used here for comparisons was constructed from a chimaera of HIV-1-SIV structures (Extended Data Fig. 3c ). b, Difference distance analysis 26 of pre-fusion BG505 and post-fusion HIV-1-SIV chimaeric gp41. Secondary structure is indicated, along with missing residues of BG505 (548-568) and of SIV (611-614). c, Superposition of post-fusion gp41 (grey) onto pre-fusion gp41 (rainbow) for a7 (left) and a9 (right) pre-fusion helices. d, HIV-1 Env entry rearrangements. Electron microscopy reconstructions (top row) with gp120 (middle) and gp41 (bottom) rearrangements between each conformational state highlighted with orange lines depicting movement of each Ca between conformations. Subunit models are shown in grey with modelling parameters and references provided in Extended Data Table 2 . Antigenic recognition of each of these states is shown in Extended Data Fig. 5 .
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superposition of pre-fusion a9 and post-fusion HR2 placed residues 634 gp41 -664 gp41 within 5 Å , with an r.m.s.d. of 3.58 Å (Fig. 3c, right) ; the substantial alignment of a9 and HR2 helices indicates that the HR2 helix is preformed in the pre-fusion structure.
Entry rearrangements of HIV-1 Env
Biosynthesis of HIV-1 Env starts with an uncleaved gp160 trimer. After cleavage, the spike condenses into the pre-fusion mature closed structure described here. In the gp120 inner domain, helix a 1 is formed, and a parallel strand exists between strands b3 and b21; in gp41, we observe helix a7 to begin around residue 571 gp41 . A partially open electron microscopy structure 27 has been reported at 6 Å , in which the trimer association domains appear to be displaced from the trimeric axis, and helical density suggests helix a7 to start several turns earlier; we modelled these rearrangements with a rigid body motion of 6 degrees for gp120 and the conversion of ,15 residues of helix a6 and connecting stretch into helix a7, which extends ,20 Å towards the target cell membrane ( Fig. 3d , middle panel; Extended Data Table 2 ).
The CD4-bound state has been visualized by a number of electron microscopy reconstructions 28, 29 and atomic-level structures 7, 22 . In this state, V1V2 separates from V3: V3 points towards the target cell 30 , and the bridging sheet 7 assembles with strand b2 forming antiparallel hydrogen bonds with b21 (as opposed to the parallel b3-b21 interaction of the pre-fusion mature closed state; notably, the only parallel b-strand in the respiratory syncytial virus (RSV) F glycoprotein pre-fusion structure also changes conformation in RSV F pre-to post-fusion transition 31 ). With layer 1 of the inner domain 23 , helix a0 forms, and Gln428 gp120 and strand b21 invert; in layer 2, inner domain rearrangements include the swapping of distinct perpendicular interactions of Trp 112 gp120 and Trp 427 gp120 (Extended Data Fig. 4 ). CD4 binding allows HR2-peptide analogues (such as C34) to bind 32 , and we can model helix a7 starting as early as 554 gp41 with Met 530 gp41 still in its membrane-proximal tryptophan clasp, as expected because 35O22 binds the CD4-bound SOSIP. 664 (Extended Data Figs 3d, e and 5c, e). We envision that Env-CCR5 interactions 33 bring the CD4-bound state close to the target cell membrane, where 'disassembling a6/assembling a7 helices' coupled to release of the Met 530 gp41 prong from its tryptophan clasp ultimately amasses the gp41 fusion peptide(s) ( Fig. 3d , second panel from right, Extended Data Fig. 3f ).
At this receptor-bound stage, it is easy to imagine the fusion peptide penetrating the target cell membrane, while strand b27 of the gp41cysteine loop remains hydrogen-bonded to the gp120 termini (and the C terminus of the gp41 ectodomain remains in the viral membrane). Rearrangement of gp41 to its post-fusion conformation may be triggered by gp120 shedding 34 , with expulsion of the gp120 termini tugging on the gp41-cysteine loop and destabilizing pre-fusion gp41.
HIV-1 rearrangements and other type I fusion machines
To determine whether the distinct elements we observed in pre-fusion gp41 were preserved elsewhere, we examined pre-fusion and post-fusion states of other type I fusion machines from influenza virus 35, 36 (a member of the Orthomyxoviridae family of viruses), RSV 31, 37 (Paramyxoviridae), and Ebola virus 38, 39 (Filoviridae) (Fig. 4a ). In all cases, a helix was observed in the gp41 pre-fusion equivalents, which corresponds in sequence to the C-terminal portion of the helix that in the post-fusion conformation comprises the interior coiled-coil characteristic of type I fusion machines 8, 9 (Fig. 4b ). With pre-fusion machines from HIV-1, influenza and Ebola viruses, the nascent pre-fusion helix adopts a coiledcoil; with RSV, a coiled-coil assembles immediately N-terminal to the nascent post-fusion helix. Despite marked differences in gp120-equivalents, similarity was observed in the overall topology of subunit interactions. Notably, all of the gp41-equivalents wrapped hydrophobic residues The pre-fusion structures are shown for a single protomer in ribbon representation with gp120-equivalent subunits in red, and gp41-equivalent subunits in rainbow (blue to orange). The trimeric post-fusion structures are shown with one subunit in rainbow (blue to orange), and the other in light and dark grey. b, The C-terminal portion of the preformed interior helix of post-fusion coiled-coil from a is shown, with fusion peptides (FP) and N-and C-terminal residues of post-fusion coiled-coils labelled, and the distance the inner coiled-coil extends between pre-fusion and post-fusion conformations indicated. c, The gp41 equivalents encircle extended b-strands of their gp120-equivalent partners. Ribbon representations are shown looking towards the viral membrane. With influenza virus, it is only the N terminus of the gp120 equivalent (HA1) that is wrapped by the gp41 equivalent (HA2), with the N terminus of HA2 completing about 20% more than a single encirclement. With RSV, it is also only the N terminus of the gp120 equivalent (F2) that is wrapped by the gp41 equivalent (F1), and the termini do not have to be expelled to transition to the post-fusion form. With Ebola, the gp41 equivalent (gp2) wraps both N and C termini strands of the gp120 equivalent (gp1), completing about 70% of a single encirclement. Such encirclement probably helps capture the energy of pre-fusion folding, which is released during the post-fusion transition to power membrane fusion.
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around extended termini (or N terminus) of their gp120-equivalents ( Fig. 4c ). Overall, the similarities in pre-fusion folding topology and in pre-fusion interior helices observed here, along with the previously observed similarity in post-fusion coiled-coils (reviewed in ref. 40 ), provide a more general and integrated view of the structural and conformational requirements of type I-mediated membrane fusion.
Glycan shielding and genetic variation
The pre-fusion mature closed conformation of HIV-1 Env is the target of most neutralizing antibodies. The newly revealed structure of a nearcomplete gp120-gp41 Env trimer ectodomain provides an opportunity to understand aggregate properties of glycosylation and variation. Glycan shielding and genetic variation have long been recognized as mechanisms to avoid antibody recognition 41 . The BG505 SOSIP.664 sequence contains 28 sequons specifying N-linked glycosylation (including a T332N mutation). We modelled high mannose glycans (either Man5 or Man9) on each sequon and calculated accessible surface for radii ranging from 1.4 Å (the radius of a water molecule) to 10 Å (the approximate radius of a single immunoglobulin domain) (Extended Data Fig. 6 ). In the Man9glycosylated model, 29% of the protein surface was solvent accessible, whereas only 3% of the surface was immunoglobulin-domain accessible. By contrast, with the fusion glycoproteins from influenza virus and RSV, 14% and 48%, respectively, of these surfaces were immunoglobulindomain accessible (Fig. 5a ).
In terms of genetic variation, we calculated the per-residue Shannon entropy of 3,943 sequences of HIV-1 (Fig. 5b ). Approximately 50% of the surface was shown to have a variability of greater than 10%, a degree of surface variation shared by influenza virus, but not by RSV. When we combined glycan shielding and genetic variation, only ,2% of the surface was immunoglobulin accessible with a variability of less than 10% (Extended Data Fig. 7 , upper panels); much of this conserved surface occurred at the membrane-proximal 'base' of the spike, which is expected to be sterically occluded by the viral membrane. To determine how this fully assembled shield compared to other conformations, we also assessed 
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Prevalence of neutralizing response in cohort Env spike of neutralizing responses identified serologically from cohorts, 2-3 and 51 years post-infection. a, The location of the neutralization epitopes for broadly neutralizing antibodies is depicted on the pre-fusion mature closed Env spike with red for CD4-binding-sitedirected antibody specificities (VRC01-, b12-, CD4-, and HJ16-like), purple for 8ANC195-like, green for V1V2-directed (PG9-like), blue for glycan-V3 specificities (PGT128-and 2G12-like), orange for 35O22-like specificities, and greenyellow for PGT151-like specificities. b, Top, broadly neutralizing epitopes on influenza virus HA (left, PDB ID 2YP7) and RSV fusion glycoprotein (right, PDB ID 4JHW). Bottom, glycan surface area and residue entropy of antibody epitopes for HIV-1, influenza virus and RSV, with bars coloured according to epitopes shown in a and b (except for epitopes not present in SOSIP.664 or where there is no atomic level definition). c, Neutralization fingerprint. For each serum, the predicted neutralization prevalence for each of the 12 antibody specificities is shown based on neutralization of 21 diverse HIV-1 strains (Extended Data Fig. 8 ).
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the immunoglobulin accessibility of the CD4-bound conformation (Extended Data Fig. 7 , lower panels). Notably, the CD4-bound conformation showed substantially higher levels of glycan-free, conserved surface, consistent with the greater ease by which antibodies reactive with the CD4-bound conformation are elicited-and by contrast, the difficulty in eliciting broadly neutralizing antibodies against the glycancovered, sequence-variable pre-fusion closed state.
Serologic recognition of pre-fusion closed Env
Despite multiple mechanisms of immune evasion that shield mature HIV-1 Env, potent broadly neutralizing antibodies do develop 42 . The structure of HIV-1 Env in the pre-fusion mature closed state allows us to map known epitopes on their most likely functional target ( Fig. 6a) and to compare the recognition of broadly neutralizing HIV-1 antibodies, with those capable of neutralizing influenza virus and RSV (Fig. 6b) .
To determine the location and prevalence of effective humoral responses, we used a serologic analysis based on serum neutralization of a panel of diverse HIV-1 isolates 20 . Sera from a cohort that had been infected for 2-3 years and from another that had been infected for more than 5 years were assessed on a panel of 21 diverse HIV-1 isolates, and the neutralization phenotypes assigned to 12 prototypic antibodyneutralization fingerprints (Fig. 6c , Extended Data Fig. 8a, b) . We then mapped the responses to the surface of the mature closed HIV-1 Env spike (Extended Data Fig. 8c, d) . The most prevalent response corresponded to the glycan-V3 epitope epitomized by antibody PGT128. CD4-binding site-directed responses, 8ANC195 responses, V1V2-directed responses, and 35O22 responses were also prevalent after 51 years. Overall, responses in both cohorts were generally in good agreement with each other, indicating little evolution in the location or prevalence of effective neutralizing responses between 2-3 and 51 years. Notably, when mapping Env sites of vulnerability, the majority of prevalent sites corresponded to Env surfaces covered by N-linked glycosylation and/ or of high sequence variability. Indeed, both PGT122 and 35O22 cocrystallized here recognize N-linked glycan, and they both utilize framework 3 insertions, in the light chain for PGT122 and in the heavy chain for 35O22 (Extended Data Fig. 9 ).
Viral evasion and immune recognition
In addition to merging virus and host-cell membranes, viral fusion machines must contend with antibody-mediated neutralization. With RSV, peak infection occurs at 5-10 months of life, as maternal antibodies wane; with influenza virus, natural infection elicits strain-specific antibodies, and evasion occurs seasonally on a global scale. HIV-1, however, confronts the immune system in each individual directly, often presenting high titre of Env antigens over years of chronic infection. These differences in evasion are reflected by structural differences in the fusion machines. The structure of the HIV-1 Env spike revealed here allows the molecular trickery behind single-spike entry 43 , glycan shielding 3 and conformational masking 44 to be visualized at the atomic level (Extended Data Fig. 10 ). Thus, avoidance of antibody avidity 45 through the ability of a single HIV-1 spike to fuse viral and target cell membranes 43 is likely to be assisted by membrane proximity of the co-receptor and membrane association of the membrane-proximal external region (MPER; Fig. 3 ); despite these differences, the HIV-1 Env spike appears to share mechanism and topology with other type I fusion machines (Fig. 4) . In terms of glycan shielding 3 , we have modelled the structure of a fully assembled glycan shield for BG505, a tier II-transmitted founder virus 46 (Fig. 5 ). Although glycan masking appears to be complete at the HIV-1 spike apex, closer to the viral membrane 'holes' in the glycan shield are observed. And with conformational masking 44 , evasion is optimal for the pre-fusion mature closed state, with receptor-binding unmasking conserved glycan-free surfaces (Extended Data Fig. 7) . Despite extraordinary glycosylation and sequence variation, the human immune system seems to be up to the challenge of generating HIV-1-neutralizing antibodies (Fig. 6 ). We note that recognition of glycosylation appears to be a trait common only to HIV-1-neutralizing antibodies and that both broadly neutralizing HIV-1 and influenza virus antibodies tolerate epitope sequence variation (Fig. 6b ). The structure of the HIV-1 Env spike described here thus reveals not only commonalities in entry and evasion with other type I fusion machines, but also commonalities in recognition by the human immune system. It remains to be seen whether an effective vaccine against HIV-1 can be developed by using the atomiclevel detail provided here, which should allow for immunogen-design strategies such as conformational stabilization 47 and nanoparticle delivery 48 ; additionally, antibody-type and ontogeny-specific strategies may be required, and template ontogenies are becoming available for some of the more commonly elicited HIV-1-neutralizing antibodies (Extended Data Fig. 8d ), such as those against the CD4-binding site 49 and V1V2 site 50 .
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
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METHODS BG505 SOSIP.664 expression and purification. The crystallized HIV-1 Env construct from strain BG505 was generated following published reports 10, 15, 16 , using BG505 GenBank accession numbers ABA61516 and DQ208458 46 ; including the 'SOS' mutations (A501C, T605C), the isoleucine to proline mutation at residue 559 (I559P), and the glycan site at residue 332 (T332N); mutating the cleavage site to 6R (REKR to RRRRRR); and truncating the C terminus to residue 664 (all HIV-1 Env numbering according to the HX nomenclature). This construct is referred to as BG505 SOSIP.664 throughout this entire manuscript.
The BG505 SOSIP.664 construct was co-transfected with furin in HEK 293 GnTI 2/2 cells using 600 mg of BG505 SOSIP.664 and 150 mg of furin plasmid DNAs as described previously 16 . Transfection supernatants were harvested after 7 days, and passed over either a 2G12 antibody-or VRC01 antibody-affinity column. After washing with phosphate-buffered saline (PBS), bound proteins were eluted with 3 M MgCl 2 , 10 mM Tris pH 8.0. The eluate was concentrated to less than 4 ml with Centricon-70 and applied to a Superdex 200 column, equilibrated in 5 mM HEPES, pH 7.5, 150 mM NaCl, 0.02% azide. The peak corresponding to trimeric HIV-1 Env was identified, pooled, concentrated and used immediately or flash-frozen in liquid nitrogen and stored at 280 uC. Fab expression and purification. PGT122 and 35O22 IgGs were expressed as previously described 51 . Heavy chain plasmids containing an HRV3C cleavage site in the hinge region were co-transfected with light chain plasmids in 293F (35O22) or GnTI 2/2 (PGT122, which is glycosylated) using TrueFect-Max transfection reagent (United Biosystems) according to manufacturer's protocol. Cultures were fed with fresh 293FreeStyle media (Life Technologies) 4 h post-transfection and with HyClone SFM4HEK293 enriched medium (HyClone) containing valproic acid (4 mM final concentration) 24 h after transfection. Cultures were then incubated at 33 uC for 6 days, and supernatants harvested and passed over a protein A affinity column. After PBS wash and low pH elution, pH of eluate was neutralized with 1 M Tris pH 8.5. Fabs were obtained using HRV3C digestion and collecting flowthrough from protein A column to remove Fc fraction. Fabs were further purified over Superdex 200 in 5 mM HEPES, pH 7.5, 150 mM NaCl, 0.02% azide. Ternary complex preparation. PGT122 and 35O22 Fabs were added to a solution of purified trimeric BG505 SOSIP.664 in fivefold molar excess for 30 min at room temperature. The complex was then partially deglycosylated by adding Endo H (50 ml) for 1 h at room temperature in the gel filtration buffer. The complex was then purified over gel filtration equilibrated in 5 mM HEPES, pH 7.5, 150 mM NaCl, 0.02% azide. Fractions were pooled, concentrated down to 5-10 OD 280 nm per ml and used immediately for crystal screening or flash frozen in liquid nitrogen and kept at 280 uC until further use. Crystallization screening. The ternary complex was screened for crystallization using 576 conditions from Hampton, Wizard and Precipitant Synergy 52 screens using a Cartesian Honeybee crystallization robot as described previously 51 and a mosquito robot using 0.1 ml of reservoir solution and 0.1 ml of protein solution. Crystals suitable for structural determination were identified robotically in 0.2 M Li 2 SO 4 , 6.65% PEG 1500, 20% isopropanol and 0.1 M sodium acetate pH 5.5. Crystals were reproduced in hanging droplets containing 0.5 ml of reservoir solution and 0.5 ml of protein solution. Optimal crystallization conditions were obtained in 16% isopropanol, 5.32% PEG 1500, 0.2 M Li 2 SO 4 , 0.1 M Na acetate pH 5.5. Crystals were cryoprotected in a solution of 15% 2R3R-butanediol, 5% isopropanol, 0.2 M Li 2 SO 4 , 6.65% PEG 1500, 0.1 M sodium acetate pH 5.5, and flash-frozen after covering with paratone N 53 . Data were collected at a wavelength of 1.00 Å at the SER-CAT beamline ID-22 (Advanced Photon Source, Argonne National Laboratory). X-ray data collection, structure solution and model building. Diffraction data were processed with the HKL2000 suite 54 . The data were corrected for anisotropy using the anisotropy server http://services.mbi.ucla.edu/anisoscale/ with truncations to 3.5 Å , 3.5 Å , 3.1 Å along a, b and c axes, respectively. Structure solution was obtained with Phaser using gp120 (PDB ID 4J6R 20 ), PGT122 (PDB ID 4JY5 19 ) and 35O22 Fv (PDB ID 4TOY 13 ) as search models. Refinement was carried out with Phenix 55 imposing PGT122, 35O22 and gp120 model-based refinement restraint during initial round of refinement. Model building was carried out with Coot 56 . The Ramachandran plot as determined by MOLPROBITY 57 showed 92.66% of all residues in favoured regions and 99.03% of all residues in allowed regions. Data collection and refinement statistics are shown in Extended Data Table 1 . Preparation of fluorescently labelled virus. Fluorescently labeled virus was prepared as described 18 . Briefly, for site-specific incorporation of fluorophores the Q3 (GQQQLG) and A1 (GDSLDMLEWSLM) peptides were inserted into the V1 and V4 loops of HIV-1 JR-FL gp160 at positions 136 and 404 (HXB2 numbering), respectively. Virus for smFRET imaging was generated by cotransfecting HEK293 cells with a 40:1 ratio of wild-type HIV-1 JR-FL gp160 plasmid pCAGGS to HIV-1 JR-FL gp160 plasmid containing the Q3 and A1 labelling peptides, in addition to pNL4-3 Denv DRT. The virus was harvested 24 h post-transfection, concentrated by centrifugation, and fluorescently labelled with donor and acceptor fluorophores through incubation with 0.5 mM Cy3B-cadaverine, 0.5 mM Cy5(4S)COT-CoA, 0.65 mM transglutaminase 58 (Sigma), and 5 mM AcpS 59 overnight at room temperature. The AcpS enzyme and the CoA-conjugated fluorophore were prepared as described 59 . DSPE-PEG 2,000 -biotin (Avanti) was then added to the reaction at a final concentration of 6 mM (0.02 mg ml 21 ), and the labelled virus was purified by ultracentrifugation for 1 h at 150,000g over a 6-18% Optiprep (Sigma) gradient. smFRET data acquisition and analysis. smFRET data were acquired and analysed as described 18 . Fluorescently labelled virions were immobilized on streptavidincoated quartz microscope slides and imaged on a prism-based total internal reflection fluorescence microscope. The donor fluorophore was excited by a 532-nm laser (Laser Quantum). The donor and acceptor fluorescence emissions were collected through a 360 water objective (Nikon), split by a 650DCXR dichroic filter (Chroma), and focused on parallel EMCCD cameras (Photometrics). Movies were recorded at 25 frames per s for 40 s. smFRET imaging was performed in buffer containing 50 mM Tris pH 7.5, 100 mM NaCl, a cocktail of triplet-state quenchers 60 , and 2 mM protocatechuic acid and 8 nM protocatechuate 3,4-deoxygenase to remove molecular oxygen 61 . Where indicated, surface-bound viruses were incubated with 0.1 mg ml 21 PGT122 and/or 0.1 mg ml 21 35O22 antibody.
All data analysis was performed using custom written Matlab software. Fluorescence trajectories were extracted from the movies, and used to calculate FRET efficiency according to FRET 5 IA/(ID1IA), where IA and ID represent fluorescence intensities of the acceptor and donor fluorophores, respectively. smFRET trajectories were identified for analysis on basis of their displaying sufficient signal-to-noise and fluorophore lifetime. FRET trajectories were compiled into histograms, which were fit to the sum of three Gaussian distributions in Matlab. smFRET revealed that the HIV-1 Env is conformationally dynamic, transitioning between three distinct conformational states. Response to various ligands identified the low-FRET state as the closed unliganded conformation of HIV-1 Env and the intermediate-and high-FRET states as the activated conformations stabilized by coreceptor and CD4 binding. Binding studies using biolayer interferometry. A fortéBio Octet Red384 instrument was used to measure binding of BG505 SOSIP.664 and BG505 gp120 molecules to a panel of antibodies (VRC01, VRC03, b6, b12, F105, PGT122, PGT128, PGT135, 2G12, 8ANC195, 17b, 2.2C, 412d, 48D, 447-52D, PG9, PG16, PGT145, VRC26.09, 35O22, PGT151) and CD4 Ig. All the assays were performed with agitation set to 1,000 r.p.m. in PBS buffer supplemented with 1% bovine serum albumin (BSA) in order to minimize nonspecific interactions. The final volume for all the solutions was 40-50 ml per well. Assays were performed at 30 uC in solid black tilted-bottom 384-well plates (Geiger Bio-One). Human antibodies (40-50 mg ml 21 ) in PBS buffer was used to load anti-human IgG Fc capture (AHC) probes for 600 s. Typical capture levels were between 1 and 1.5 nm, and variability within a row of eight tips did not exceed 0.1 nm. Biosensor tips were then equilibrated for 180 s in PBS/1% BSA buffer before binding assessment of the BG505 SOSIP.664 and BG505 gp120 molecules in solution for 300 s; binding was then allowed to dissociate for 300 s. Parallel correction to subtract systematic baseline drift was carried out by subtracting the measurements recorded for a sensor without monoclonal antibody incubated in PBS/1% BSA. Data analyses were carried out using Octet software, version 8.0. Difference distance analysis. Difference distance matrices 26 were produced by distance sorting atom positions and plotting with the program DDMP 62 . Surface plasmon resonance analysis. Affinities and kinetics of binding of antibodies 35O22 and PGT151 to BG505 SOSIP.664 soluble trimer were assessed by surface plasmon resonance on a Biacore T-200 (GE Healthcare) at 20 uC with buffer HBS-EP1 (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, and 0.05% surfactant P-20). In general, mouse anti-human Fc antibody was first immobilized onto two flow cells on a CM5 chip at ,10,000 response units (RU) with standard amine coupling protocol (GE Healthcare). Either CD4-Ig, 2G12 IgG or 17b IgG was then captured on both flow cells by flowing over a 200 nM solution at 5 ml min 21 flow rate for two minutes. This was followed by a 1-min injection of 1 mM human Fc on both flow cells to block unliganded mouse anti-human Fc antibody. The captured 2G12, CD4 or 17b were used to immobilize BG505 SOSIP.664 trimer on only one flow cell, with no trimer captured on the other flow cell (reference cell). For capturing with 2G12 or CD4-Ig, 500 nM of unliganded trimer was used, whereas, a complex of 500 nM trimer 1 1,500 nM sCD4 was used for capturing with 17b. Antibody Fab fragment solutions in HBS-EP1 buffer, at twofold dilutions starting from 885 nM, 600 nM and 460 nM for 35O22, PGT151 and PGT145, respectively, were injected over the captured trimer channel and the reference channel at a flow rate of 50 ml min 21 for 2 min and allowed to dissociate for 3-30 min depending on the rate of dissociation of each interaction. The cells were regenerated with two 10 ml injections of 3.0 M MgCl 2 at a flow rate of 100 ml min 21 . Blank sensorgrams were obtained by injection of same volume of HBS-EP1 buffer without antibody Fab fragments. Sensorgrams of the concentration series were corrected with corresponding blank curves and fitted globally with Biacore T200 evaluation software using a 1:1 Langmuir model of binding. The stoichiometry of binding of antibodies to the trimer RESEARCH ARTICLE were estimated by normalizing the maximal response (R max ) values to the amount of trimer captured and performing linear regression analysis using the R max values for the antibodies with known stoichiometries. Modelling of missing loops, side chains and the N-linked glycan shield. Missing loops not defined in the HIV-1 Env trimer crystal structure (V2 and V4) were modelled using Loopy 63 . Missing side chains were modelled with Scap 64 .
To model the N-linked glycan shield, we first determined all possible N-linked sequons in the BG505 HIV-1 Env trimer sequence (28 sequons). All glycans observed in the structure were removed before modelling. A conserved glycan 241 gp120 , not present in the BG505 sequence, was added. A single asparagine residue in each sequon was targeted for computational N-linked glycan addition using a series of oligomannose 9 rotamer libraries at different resolutions. In constructing the rotamer libraries, the asparagine side chain rotamers were also considered. To avoid a combinatorial explosion in the search space, select torsion angles in the oligomannose 9 rotamer libraries were allowed to vary in increments between 30-60 degrees. We used an overlap factor (ofac) to screen for clashes between the sugar moieties and the trimer structure. The ofac between two non-bonded atoms is defined as the distance between two atoms divided by the sum of their van der Waal's radii. For the modelling carried out here, we set the ofac to a value of 0.60. For sterically occluded positions, the ofac was set to 0.55. To remove steric bumps between sugar moieties, all models were subjected to 100 cycles of conjugate gradient energy minimization using the GLYCAM 65 force field in Amber12 66 with a distance-dependent dielectric.
Mapping sequence variability onto trimer structure. For each of HIV-1 Env, influenza virus HA, and RSV F, residue sequence variability was computed as the Shannon entropy for each residue position, based on representative sets of 3,943 HIV-1 strains, 4,467 influenza virus strains, and 212 RSV strains, respectively. Residues were coloured based on the computed entropy values, on a scale of white (conserved) to purple (variable). Chronically infected cohort information. In the CHAVI 001 cohort, high-risk subjects were screened for HIV-1 infection by ELISA, western blotting, and plasma RNA to recruit individuals with acute HIV infection, who were then followed for ,2 years until plasma neutralization breadth developed 67 . In addition, a group of individuals were enrolled in the CHAVI 001 or CHAVI 008 cohorts who were chronically infected with HIV-1 strains clade A, B or C, and were screened for plasma neutralization breadth. The trial participants were enrolled at sites in Tanzania, South Africa, Malawi, the United States, and the United Kingdom 68 . Both CHAVI001 and CHAVI008 protocols were approved by the institutional review boards of each of the participating institutions where blood samples were received or processed for analysis, and informed consent was obtained from all subjects. Serum neutralization fingerprinting analysis. The prevalence of effective neutralizing responses against HIV-1 Env in cohorts from 2-3 and 51 years postinfection was estimated using a neutralization fingerprinting approach, as described previously 20 . Briefly, serum neutralization over a set of 21 diverse viral strains was compared to neutralization of the same viruses by a set of broadly neutralizing antibodies grouped into 12 epitope-specific antibody clusters. For each serum, the relative prevalence of each of the 12 antibody specificities was estimated by representing serum neutralization as a linear combination of the monoclonal specificities, with prevalence values of 0.2 deemed as positive. Sera with less than 30% breadth on the 21-virus panel as well as sera with high residual values from the computation (data not shown) were not included in the analysis. For mapping prevalence values onto the BG505 SOSIP.664 structure, residues part of multiple antibody epitopes were coloured according to the respective antibody specificity with the highest prevalence in the 51 years cohort. Antibody neutralization was measured using single-round-of-infection HIV-1 Env-pseudoviruses and TZM-bl target cells, as described previously 69 . Neutralization curves were fit by nonlinear regression using a 5-parameter hill slope equation as previously described 69 . Epitope analysis for HIV-1 Env, influenza virus HA and RSV F antibodies. Glycan usage and average residue entropy were calculated for seven representative HIV-1 Env (VRC01, b12, CD4, 8ANC195, PG9, PGT122, 2G12 and 35O22) 7, 51, [70] [71] [72] [73] , four representative influenza virus HA (2D1, C05, F10 and CR8043) [74] [75] [76] [77] , and three representative RSV F (D25, Motavizumab and 101F) 31, 78, 79 epitopes based on their respective crystal structures. The selection of the flu antibodies was done as follows: F10 (stem targeting) and C05 (head targeting) were selected based on their crossneutralizing ability for group 1 and group 2 of influenza virus A. CR8043 (group 2 specific) and 2D1 (H1 specific), which target distinct regions from F10 and C05 at the stem and head of the HA respectively, were also selected for epitope analysis. An antigen residue was defined as an epitope residue if it had a non-zero buried surface area in the crystal structure. The fraction of glycan surface area in an epitope was calculated as the buried surface area of epitope glycans divided by the buried surface area of the full epitope. Unpaired nonparametric Mann-Whitney test 80 was used to quantify the statistical difference between glycan fraction or average residue entropy for HIV-1 versus influenza virus or RSV antibody epitopes.
Figures. Structure figures were prepared using PYMOL 81 . PDB IDs are referenced throughout except for 2HMG 82 , 1QU1 83 , 4MMU 47 , 3RRT 37 , 3CSY 39 and 2EBO 84 in Fig. 4 ; 2YP7 85 and 4JHW 31 in Figs 5 and 6 and PDB ID 3HI1 86 in Extended Data  Table 2 .
Interfaces. Interactive surfaces were obtained from PISA (http://www.ebi.ac.uk/ pdbe/pisa/). Figure 2 | HIV-1 subunit interactions: principle component analysis and interface contacts. a, Minimum-bounding box, generated by principle component analysis, encasing 90% of the HIV-1 Env gp120-gp41 protomer. Each gp120-gp41 blade forms a rectangle of height of ,100 Å , width of ,65 Å , and thickness of ,35 Å . Subunits are displayed in ribbon representation with gp41 coloured rainbow and gp120 coloured and labelled red. As previously visualized 10, 11 , the membrane-distal portion of the rectangle is made up of the gp120-outer and -inner domains, with the central 7-stranded b-sandwich of the inner domain occupying the trimer-distal, membraneproximal portion of gp120. We have now resolved the rest of the spike: the membrane-proximal portion of the rectangle is made up of gp41, with the membrane-distal portion of gp41 closest to the molecular threefold axis occupied by helix a7 (which corresponds in register to the C-terminal portion of the post-fusion HR1 helix of gp41), and the rest of gp41 folding around N and C termini strands of gp120, which extend over 20 Å towards the viral membrane. Of the four helices, a6 kinks at residue 537 gp41 and a9 kinks at residue 637 gp41 ; backbone H-bonding is less ideal at residues 663 gp41 and 664 gp41 . b, Different views of trimeric protomer association. The protomer association at the membrane-distal trimer apex occurs through the corners of the minimum-bounding box, whereas the association at the membraneproximal region occurs with substantial interpenetration of the minimumbounding box; these interaction differences and the protruding nature of the gp120 outer domain result in the overall mushroom shape of the trimer.
Extended Data
c, gp120-gp41 interface. Ribbon representation of gp120 (red) and gp41 (rainbow from blue N terminus to orange C terminus), with gp120 residues that interact with gp41 shown in surface representation and gp41 residues that interact with gp120 shown in semi-transparent surface. A complete list of subunit interactions is provided in Supplementary Table 1 . Membraneproximal interactions are further stabilized by hydrophobic interactions, which gp41 makes with the N and C termini of gp120, such as between Trp 35 gp120 and Pro609 gp41 and between Trp 610 gp41 and Pro498 gp120. d, Wheel diagram representation of a7 coiled-coil in the pre-fusion mature closed conformation of gp41 as generated by DrawCoil 1.0: http://www.grigoryanlab.org/drawcoil/ (ref. 94 ). e, gp41-trimer interfaces as viewed from the viral membrane in ribbon and surface representation (90u rotation from Fig. 2c ). f, BG505 SOSIP.664 sequence with residues identified by mutagenesis [95] [96] [97] [98] [99] [100] [101] to be important for gp120/gp41 association underlined. Residues that were found to interact between gp120 and gp41 by examination of the crystal structure are indicated in red (intra-protomer interactions) and in brown (inter-protomer interactions). Sites of N-linked glycosylation are shown in green; glycan N88 is shown in red because it is part of the gp120/gp41 interactions; no density was observed for potential N-linked glycans at residues 185, 398, 406, 411, 462 and 625. Residues that were disordered in the crystal structure are grey. SOS (A501C/T605C) and IP (I559P) mutations are labelled in bold and italics. Dots indicate residues not present in the BG505 sequence. HIV-1-SIV post-fusion chimaera, and liganded interactions. a, Modelling of gp41 residues 548-568. At low contour, suggestive density is observed that might correspond to the connection between a6 and a7 helices. This density appeared to be crystal dependent and might be related to inherent flexibility, functional rearrangements, asymmetry between protomers, or combinations of these factors. To investigate the degree to which a model for this region might be defined, we built and refined two different models for this region: electron density (blue) shown for 2F o 2 F c density at 1s contour; gp41 (rainbow colour from blue to orange) shown in ribbon representation with side chains; gp120 (red) shown in ribbon representation. The location of the I559P mutation is indicated. b, The two models from panel a are superimposed and shown in perpendicular orientations. c, HIV-1-SIV post-fusion chimaera. Sequences of HIV-1 gp41 from pre-fusion structure (BG505 strain, PDB ID 4TVP), postfusion structure (HIVpost, PDB ID 2X7R 24 ) and SIV gp41 post-fusion structure (SIVpost, PDB ID 2EZO 25 ) are aligned with secondary structure indicated. Residues that were used to make the post-fusion HIV-1-SIV chimaera used in Fig. 3 are highlighted in red. d, Binding residues of representative fusion-intermediate entry inhibitors or antibodies mapped onto the structure of pre-fusion HIV-1 Env spike [102] [103] [104] . Top, ribbon representation of pre-fusion envelope protomer A (gp120 in red and gp41 in blue) at two orientations, with the binding residues of the fusion-intermediate inhibitors 5-helix 104 and T20 102, 103 and of monoclonal antibody D5 92 shown in orange, green and yellow, respectively. Bottom, surface representation of the pre-fusion envelope trimer, with inhibitor and antibody binding residues mapped onto the surfaces of all protomers (A, B, C). gp120 is coloured grey and gp41 is coloured in shades of blue, depending on protomer. Binding residues of fusion-intermediate inhibitors 5-helix, T20 and monoclonal antibody D5 are shown in same colour shades as in the top panels. e, 5-helix, T20 and D5 Fab (all coloured magenta and grey) docked onto a model of fusion-intermediate gp41 (coloured as in d). f, A previously defined binding pocket on post-fusion gp41 is recognized by pre-fusion gp41 tryptophan-clasp residues Trp 628 and Trp 631. Shown is a surface representation of gp41 5-helix protein 104 (left, with N-heptad repeat (NHR) helices coloured in shades of green and C-heptad repeat (CHR) helices coloured in shades of orange). The footprint of gp41 tryptophan-clasp residues Trp 628 and Trp 631 is shown in magenta (middle) and that of a representative NHR-specific neutralizing antibody, D5, in yellow 92, 105, 106 (right).
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Extended Data Figure 5 | Antigenic profiles of HIV-1 envelope conformational states. a, Qualitative recognition of HIV-1 envelope by diverse antibodies is shown for five conformational states. Green bars indicate reported recognition and red bars no recognition; absence of a bar indicates that recognition is undefined. The compiled data are from cited references and experiments described in this figure. Note references 112-127 are cited here. b, Octet Biosensorgrams of BG505 SOSIP.664 (left) and BG505 gp120 (right) binding to human monoclonal IgGs. The dotted line indicates the beginning of the dissociation phase and the maximal specific binding after 300 s reported in the table (2, ,0.05 response units (RU); 1, 0.05 RU to 0.25 RU; 11, 0.25 RU to 0.5 RU; and 111, .0.5 RU). BG505gp120 did not contain the T332N mutation (no glycan at that position). Both proteins were made in GnTi 2/2 . We note that antigenicity of the BG505 SOSIP.664 and BG505 gp120 protein varied depending on the assay done. Thus, using surface plasmon resonance (SPR), no CD4i antibody binding was detected while some binding could be observed using biolayer interferometry. Although PG9 bound BG505 gp120 in ELISA 16 , it did not bind in biolayer interferometry format. We observed 447-52D binding, while it was not observed in previously published ELISA 16 . c, SPR binding affinities of 35O22, PGT151 and PGT145 to BG505 SOSIP.664 and influence of sCD4. d, Estimation of binding stoichiometry for 35O22, PGT151, and PGT145 to trimeric BG505 SOSIP.664 by SPR and comparison to published data 13, 107, 108 . e, Effect of sCD4 and sCD4/17b on binding of antibodies 35O22 and PGT151 to BG505 SOSIP.664 by SPR. The structure of a pre-fusion mature closed state of HIV-1 provides a critical addition to the pantheon of HIV-1 Env structures with atomic-level detail. Moreover, antibodies 35O22 and PGT151, which bind specifically to the trimeric pre-fusion conformation of gp41, provide new tools by which to assess the conformational state of gp41 13, 107, 109 . The binding of antibodies 35O22 and PGT151 to BG505 SOSIP.664 trimer was tested in the presence of the CD4 receptor and the 17b antibody 110 (a co-receptor surrogate which recognizes a bridging sheet epitope that overlaps the site of co-receptor recognition). In the case of antibody 35O22, CD4 binding to the BG505 SOSIP.664 trimer affected the kinetics, affinity and stoichiometry of binding. 35O22 bound to BG505 SOSIP.664 with an 8.4-fold reduced affinity, primarily contributed by an increased rate of dissociation. The overall binding level (R max ) normalized to the average level of trimer captured (see also panel d) was lower, suggesting substoichiometric binding. Capturing the trimer on a CD4-Ig surface reduced normalized R max for PGT151 compared to the 2G12 capture format, suggesting reduced stoichiometry for PGT151 binding to trimer pre-bound with CD4, although kinetics and affinity of interaction were similar. A BG505 SOSIP.664 trimer 1 sCD4 complex captured onto a 17b surface-bound 35O22 but showed no detectable binding to PGT151.
Extended Data Figure 7 | Glycan shield and sequence variability for HIV-1 pre-fusion mature closed and CD4-bound conformations. Many conformations of HIV-1 Env divert the immune response. Thus for example, shed gp120 and post-fusion gp41 represent dominant viral antigens; however, these forms of Env are not functional, and antibodies that only target them are not neutralizing. Functional conformations, however, may be significantly shielded from the neutralizing antibody. The CD4-bound conformation of HIV-1 Env, for example, is only functionally present when the viral and targetcell membranes are in close proximity, and the exposed co-receptor binding site (including V3-and CD4-induced epitopes) is spatially occluded from neutralizing antibody. Here we provide models for the pre-fusion closed state versus the CD4-bound conformation, which display the fully assembled glycan shield and surface Env variability. Env N-linked glycans are depicted in light green (conserved; greater than 90% conservation) or dark green (variable; less than 90% conservation) on the mature closed Env structure and modelled CD4-bound conformation. Env sequence variability is shown from white to purple (conserved to variable). A conserved glycan at residue 241 gp120 not present in the BG505 sequence is shown in yellow-green. As can be seen, the pre-fusion closed state has few glycan-free surfaces, whereas the CD4bound state exposes substantial glycan-free conserved surface.
Extended Data Figure 8 | Prevalence of neutralizing responses identified serologically from cohorts from 2-3 years and 51 years post infection. a, Serum neutralization on 21-strain virus panel. ID 50 s (reciprocal dilution at which 50% of the virus is neutralized) are shown for serum (rows) titrated against HIV-1 viral strains (columns). b, For each serum, the predicted neutralization prevalence for each of 12 antibody specificities is shown based on neutralization of 21 diverse HIV-1 strains. Values of at least 0.2 were considered positive and counted toward the overall cohort prevalence percentages in Fig. 6c . c, Prevalence of antibody specificities onto the HIV-1 Env, coloured as indicated in the bar graph. d, The antibody specificities for high serum prevalence in the 51 years cohort are depicted by Fabs of representative antibodies binding the BG505 SOSIP.664 Env trimer, shown in grey ribbon representation, with glycans as green sticks. Note that while prevalence between the two cohorts showed good correspondence, there were notable differences, for example, between PGT151 at 2-3 years and 51 years in this study as well as between the cohorts analysed here and in ref. 13 .
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